We are live on ! Find out more
JB

Julian Baker Baker Bros. Advisors

AUM $20B
1-Year Est. Return 154.41%
 

Julian Baker is co-managing member of Baker Bros. Advisors, a firm renowned for deep specialization in biotechnology and life sciences. The firm is known for concentrated positions, long holding periods, and scientific diligence that goes well beyond typical generalist research. Baker Bros. filings are closely watched by healthcare investors for signals in clinical-stage and commercial biotech.

This Fund
S&P 500
This Quarter Est. Return
+5.06%
1 Year Est. Return
+154.41%
3 Year Est. Return
+448.58%
5 Year Est. Return
+670.61%
10 Year Est. Return
+4,743.65%
AUM
$11.8B
AUM Growth
+$261M
Cap. Flow
+$368M
Cap. Flow %
3.12%
Top 10 Hldgs %
80.71%
Holding
127
New
5
Increased
21
Reduced
20
Closed
13

Top Buys

Rank Stock Value
1
ONC
BeOne Medicines Ltd
ONC
+$268M
2
SGEN
Seagen Inc. Common Stock
SGEN
+$210M
3
AVXS
AveXis, Inc. Common Stock
AVXS
+$46.6M
4
HRTX icon
Heron Therapeutics
HRTX
+$44.6M
5
ACGN
Aceragen Inc
ACGN
+$41M

Top Sells

Rank Stock Value
1
ABLX
Ablynx NV
ABLX
+$98.3M
2
RXDX
Ignyta, Inc.
RXDX
+$37M
3
IMGN
Immunogen Inc
IMGN
+$16.4M
4
SGMO
SANGAMO THERAPEUTICS INC
SGMO
+$10.8M
5
ANAB icon
AnaptysBio
ANAB
+$10.2M

Sector Composition

Rank Sector Weight
1 Healthcare 99.05%
2 Technology 0.01%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
INCY icon
1
Incyte
INCY
$25.9B
$2.85B 24.18%
34,230,751
+228
+0% +$20.6K
SGEN
2
DELISTED
Seagen Inc. Common Stock
SGEN
$2.59B 21.99%
49,575,409
+3,849,853
+8% +$210M
ONC
3
BeOne Medicines Ltd
ONC
$42.4B
$979M 8.3%
5,829,429
+1,980,198
+51% +$268M
ALXN
4
DELISTED
Alexion Pharmaceuticals
ALXN
$954M 8.08%
8,555,894
+2,030
+0% +$243K
BMRN icon
5
BioMarin Pharmaceuticals
BMRN
$12.9B
$615M 5.21%
7,583,084
– –
ACAD icon
6
Acadia Pharmaceuticals
ACAD
$5.08B
$612M 5.19%
27,228,338
– –
GHDX
7
DELISTED
Genomic Health, Inc.
GHDX
$431M 3.66%
13,789,936
+8,834
+0.1% +$293K
ASND icon
8
Ascendis Pharma A/S
ASND
$16.6B
$186M 1.57%
2,837,352
+218,534
+8% +$12.3M
NGNE icon
9
Neurogene
NGNE
$773M
$154M 1.3%
546,708
– –
AVXS
10
DELISTED
AveXis, Inc. Common Stock
AVXS
$144M 1.22%
1,167,157
+392,157
+51% +$46.6M
HRTX icon
11
Heron Therapeutics
HRTX
$60.4M
$139M 1.18%
5,025,298
+1,964,657
+64% +$44.6M
DBVT
12
DBV Technologies
DBVT
$914M
$127M 1.08%
550,956
– –
ABLX
13
DELISTED
Ablynx NV
ABLX
$119M 1.01%
2,176,802
-1,984,316
-48% -$98.3M
SAGE
14
DELISTED
Sage Therapeutics
SAGE
$104M 0.88%
646,828
+30,314
+5% +$5.15M
ARRY
15
DELISTED
Array Biopharma Inc
ARRY
$92.3M 0.78%
5,656,196
– –
ONCE
16
DELISTED
Spark Therapeutics, Inc. Common Stock
ONCE
$92.2M 0.78%
1,384,130
– –
NBIX icon
17
Neurocrine Biosciences
NBIX
$15.5B
$78.3M 0.66%
944,624
-60,000
-6% -$5.07M
MRTX
18
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$78.3M 0.66%
2,549,461
– –
ARGX icon
19
argenx
ARGX
$65B
$77.4M 0.66%
961,754
– –
MDGL icon
20
Madrigal Pharmaceuticals
MDGL
$11.9B
$71.9M 0.61%
615,684
– –
ACGN
21
DELISTED
Aceragen Inc
ACGN
$71.1M 0.6%
284,413
+149,603
+111% +$41M
AMRN
22
Amarin Corp
AMRN
$298M
$68.2M 0.58%
1,133,475
– –
BCRX icon
23
BioCryst Pharmaceuticals
BCRX
$2.44B
$66.8M 0.57%
14,012,172
+15,000
+0.1% +$77.1K
PHXM
24
DELISTED
PHAXIAM Therapeutics S.A.. American Depositary Shares
PHXM
$64.9M 0.55%
309,007
– –
CERS icon
25
Cerus
CERS
$566M
$58.9M 0.5%
10,749,937
+1,004,728
+10% +$4.57M
1
2 3 4 5

Similar funds

ASRS
Arizona State Retirement System Phoenix, Arizona $19.9B AUM 44.71% 1-Year Est. Return
FWIA
Fort Washington Investment Advisors Cincinnati, Ohio $19.9B AUM 22.19% 1-Year Est. Return
CWP
Capital Wealth Planning Naples, Florida $20B AUM 25.34% 1-Year Est. Return
SFA
Sequoia Financial Advisors Akron, Ohio $20.1B AUM 24.77% 1-Year Est. Return
MGP
M&G plc London, United Kingdom $20.1B AUM 16.62% 1-Year Est. Return
JAM
Jupiter Asset Management London, United Kingdom $20.2B AUM 29.18% 1-Year Est. Return
Verition Fund Management
Verition Fund Management Greenwich, Connecticut $19.7B AUM 39.39% 1-Year Est. Return
Select Equity Group
Select Equity Group New York $20.2B AUM 17.52% 1-Year Est. Return

Julian Baker's Q1 2018 Portfolio in Review

As of Q1 2018, Julian Baker held 127 positions worth $11.8B, up 2.3% from $11.5B the previous quarter. Its ten largest holdings account for 81% of the portfolio.

Julian Baker deployed $368M of net new capital in Q1 2018, opening 5 new positions and adding to 21 existing holdings. Its largest new stake was Yarrow Bioscience: 194 shares worth $26.3M.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, up from 99% a quarter earlier, followed by Technology.

On the sell side, the largest reduction was Ablynx NV, an estimated $98.3M trimmed.

  • Julian Baker's largest Q1 2018 buy was Yarrow Bioscience: 194 shares worth $26.3M.
  • Julian Baker added most to BeOne Medicines Ltd in Q1 2018, an estimated $268M increase.
  • Julian Baker's biggest Q1 2018 reduction was Ablynx NV, cutting an estimated $98.3M.
  • Julian Baker fully exited Ignyta, Inc. in Q1 2018, selling an estimated $37M.
  • Julian Baker's ten largest holdings make up 81% of its $11.8B portfolio in Q1 2018.
  • Julian Baker opened 5 new positions and closed 13 in Q1 2018.
  • Julian Baker's portfolio value rose 2.3% quarter-over-quarter to $11.8B.

Based on Baker Bros. Advisors's 13F filing for Q1 2018, filed 15 May 2018.